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OUTLINE
• Usual Interpretations of Recent Economic Transformations
- New Economy Thesis
- Financialization Thesis
• The Productivity Bias; The Need of a Power Theory of Value
- What is being accumulated?
- Differential Accumulation
• An Illustration with Pharmaceuticals
- New hypothesis
Structural Transformations in Advanced
Capitalism: Knowledge or Finance?
1- «New Economy Thesis» (Cognitive Capitalism): Transformations are due 
to new intangible sources of production and wealth, chiefly knowledge 
and intelligence. Accumulation regime based on creativity and permanent 
innovation.   (Rifkin, Castells, Matisse-Issys, Negri, Sveiby, Lev)
2- Financialization or «Shareholder Capitalism Thesis»: the rise of 
institutional investors created a new regime of growth where firms 
restructure the division of labour under new models of corporate
governance to maximize shareholder value. Finance capital captures the
real economy and operates a major income redistribution towards
investors. (Aglietta, Plihon, Krippner, Henwood, Chesnais, Stanford)
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The New EconomyThesis:
Intangible Assets as % of Tangible Assets
« Market-to-Book Value » for Dow Jones Industrial Average, 1920-2004
Source: Sveiby (1998), Data updated with Value Line
"Jimbo Index"
 Real vs Financial Assets in Canada (as a % of GDP), 1961-2004
Source: Jim Stanford (1999), Statistics Canada (table 380-0016) compiled by Eric Pineault
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Financialization: Financial Capture of the Real Economy
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Output per hour Hourly Compensation
Hourly Productivity and Hourly Real Compensation per Worker 
for US Non-Farm Business Sectors Between 1947-2005 
(1947=100)
Source: Bureau of Labor Statistics
The Elite takes all
Growth in After Tax Real Income for US Households
According to their Income Level (1947-1979 & 1979-2003)
Source: Congressional Budget Office, Effective Tax Rates (Various years)
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Problem for both interpretations: Productivity Bias
- Conceit that there is a « real » economy, producing real wealth to which correspond 
economic values. 
- Capital accumulation remains an accumulation of wealth, of useful commodities
produced in the past.
Thorstein Veblen’s alternative: dichotomy between Business and Industry
(Theory of Business Enterprise; Absentee Ownership)
- The industry (shared technology by the community) that produces wealth is
inherently a societal process where every product embody the entire history of human
knowledge. 
- Business (and economics) is about the creation of pecuniary value and the capture of
earnings.
- Capital is a claim over putative earning-capacity, a claim not on the usufruct of the
past but on future earnings. Capital is only financial capital. 
- The corporation is a better form of economic organization to maximize earnings, not
by maximizing production but by maximizing the control over productive capacities.
- Tangible assets are capitalized in terms of Sabotage capacity; Businessmen thus
take the industry hostage and can reclaim a ransom. 
- The bulk of any corporation’s capitalization is made of intangible assets, which are 
any durable earning-capacity (due to any institutional setting, like conventions or state 
power).
Shimson Bichler and Jonathan Nitzan’s Differential Accumulation
- Capitalism has to be analyzed as a whole social order, in which accumulation is 
not an offshoot of production, but, rather, the manifestation of a struggle over the 
shaping of the social process between dominant groups and the rest of society, 
as well as between those groups themselves
-Capitalized Earning-Capacity represents a claim, not for a share of the output, 
but for a share of control over the social process. Capital is the commodification
of capitalist power and thus capital accumulation is an accumulation of capitalist
power
- Power needs to be measured in differential terms. In the capitalist logic, it is not
about the search for maximum profit, it is the search to maximize profits 
compared to others, it is to beat the average.
- Capital Accumulation should thus be measured in differential terms (Differential
accumulation) by comparing a group’s (or corporation’s) combined capitalization 
to that of an average unit of capital.
US World Market Share in Pharma:
Sales: 48%
Production: 29%
R&D: 49%
Source: IMS, EFPIA, OECD Health Data
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All Fortune 500 
Pharma firms in Fortune 500
Big Pharma Differential Accumulation; 
Profits of an average US pharmaceutical firm as compared to an average 
firm in the Fortune 500 (1954-2005; in millions of constant 1984 US$)
Source: Fortune 
Are we entering a new era of innovation?
Global Introductions of New Chemical Entities 1961-2005
Sources: 1961-1985: Erika Reis-Arndt (1987)
1986-2005: IMS Lifecycle New Product Focus Database
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Breadth in Differential Accumulation
BUY-TO-BUILD RATIO
Mergers and Acquisitions in proportion to Gross Capital Formation for US Pharmaceuticals and All
US Sectors, 1981-2003  (log scale)
Source: -Bichler and Nitzan (2002)
-for all sectors: BEA and Statistical Abstract of the United States
-for pharmaceuticals: OECD Health Data, Thomson Financial
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Depth in Differential Accumulation
Differential Returns on Revenues (ROR) Between Big Pharma and 
Fortune 500, 1954-2005
Source: Fortune Magazine
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CONCLUSION:
New economy Thesis and the Financialization Thesis are unable to 
account for structural transformations in the Global Pharmaceutical
Business.
By considering capital in terms of power, of control over society, the
differential accumulation analytical framework opens the way to new 
hypothesis:
-Structural Competition: Dominant Capitalist groups compete by 
transforming willingly the socio-economic institutional settings to 
increase their strategic control over the industry and society.
- M&As are a result of externalizing R&D where dominant firms
simply buy back promising results by smaller firms or universities
(Bayh-Dole Act in 1980).
- Differential ROR could maybe be explained by the extension of
intellectual property rights resulting from the activism of American
pharmaceutical companies (especially Pfizer).
